Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Episode 40 with Dr. Raj Kapoor on a clinical trial of phenytoin
USPTO list of patent term extensions
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
ACTRIMS-ECTRIMS 2014 -- Day 3, morning
Glatiramer promotes oligodendroglial cell maturation in a cuprizone-induced demyelination model.
The Role of the Gut Microbiome on Multiple Sclerosis Risk and Progression
American Academy of Neurology Fall Conference 2014
Prevention and Mitigation of Experimental Autoimmune Encephalomyelitis by Murine β-Defensins via Induction of Regulatory T Cells.
Primary progressive multiple sclerosis-why we are failing.
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Risk alleles for multiple sclerosis identified by a genomewide study.
Episode 43 with Dr. May Han on following patients through the course of their disease
Episode 36 with Dr. Jenny Ting on the inflammasome
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.
Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients
ACTRIMS-ECTRIMS 2014 -- Day 4
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Episode 57 with Dr. Timothy Vollmer, on the early phase 3 ocrelizumab results and implications
The Oxford English Corpus: Facts about the language, The Story of Dictionaries
The complex role of estrogens in inflammation.
Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity.

Pages